Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dronabinol/palmitoylethanolamide - SciSparc

Drug Profile

Dronabinol/palmitoylethanolamide - SciSparc

Alternative Names: SCI-110; THX OSA01; THX RS01; THX-110; THX-TS01

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapix Biosciences
  • Developer SciSparc; The Israeli Medical Center for Alzheimer's
  • Class Amides; Analgesics; Anti-inflammatories; Antidementias; Antiemetics; Antineoplastics; Antivirals; Appetite stimulants; Behavioural disorder therapies; Cannabinoids; Chromans; Ethanolamines; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Palmitic acids; Sleep disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Agitation; Alzheimer's disease; Gilles de la Tourette's syndrome; Sleep apnoea syndrome
  • No development reported Back pain

Most Recent Events

  • 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the UK
  • 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Japan and other jurisdictions
  • 24 Oct 2023 SciSparc has patent protection for Dronabinol/palmitoylethanolamide covering combinations of cannabinoids and N-Acylethanolamines in Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top